• CX-4945 (Silmitasertib) in Reliable Cell Assays

  2026-08-10

  This scenario-driven guide shows how CX-4945 (Silmitasertib), SKU A8330, can help researchers interpret viability, proliferation, apoptosis, and cell-cycle data through a CK2-centered experimental framework. It combines formulation guidance, mechanistic controls, assay troubleshooting, and evidence from cancer research to support more reproducible laboratory decisions.

• Roscovitine Workflows for CDK and Tumor Studies

  2026-08-09

  Roscovitine enables controlled dissection of CDK2, CDK5, and CDC2 signaling, reversible late-prophase arrest, and tumor-response mechanisms. This practical guide connects cell-cycle assays with radiotherapy–immunotherapy research while clearly separating established evidence from hypothesis-generating combination designs.

• AZD0156: A Pharmacology-First DDR Strategy

  2026-08-08

  AZD0156 is a selective ATM kinase inhibitor for studying DNA double-strand break signaling and treatment response. This pharmacology-first guide connects ATM biology with lessons from systematic kinase-inhibitor profiling to improve assay design and interpretation.

• AZD1480: A JAK2/STAT3 Assay Strategy

  2026-08-07

  AZD1480 is a potent JAK2 inhibitor for dissecting tumor-intrinsic STAT3 activation after IDO1 blockade. This guide translates single-cell evidence into compartment-resolved assays, pharmacology controls, and practical interpretation.

• Lypressin Acetate: Mechanistic Evidence and Clinical Utility

  2026-08-07

  Lypressin acetate is a natural vasopressin analog used in the treatment of diabetes insipidus. Its mechanism as a G protein-coupled receptor agonist enables potent antidiuretic and vasopressor activity. Recent data highlight its reproducible bioactivity and emerging antiviral applications.

• Central Circuits in Opioid-Induced Mechanical Hypersensitivi

  2026-08-06

  Yin et al. (2024) delineate a brain-to-spinal opioid pathway mediating mechanical opioid-induced hypersensitivity (OIH) and tolerance in mice. Their work clarifies the central mechanisms underlying morphine’s paradoxical effects on pain sensitivity, offering new targets for pain modulation research.

• IDO1 Inhibition Drives Tumor-Protective STAT3 Activation via

  2026-08-06

  This study reveals that pharmacological inhibition of IDO1, while enhancing antitumor immunity, paradoxically activates the tumor-intrinsic JAK2/STAT3 pathway through IL-6 secretion, leading to tumor-protective effects. The findings highlight the mechanistic basis for combining JAK2/STAT3 pathway inhibitors with IDO1 blockade to improve cancer immunotherapy outcomes.

• MDL 28170: Elevating Translational Neuroprotection Strategie

  2026-08-05

  Explore how MDL 28170, a selective calpain and cathepsin B inhibitor, advances neuroprotection research by bridging mechanistic insight with translational opportunity. Grounded in recent mechanistic studies and best practices, this thought-leadership piece guides researchers on leveraging MDL 28170 for reproducible apoptosis, neuroprotection, and ischemia-reperfusion injury models—delivering actionable workflow protocols, competitive positioning, and a forward-looking perspective.

• Angiotensin II in Vascular Research: Protocols and Innovatio

  2026-08-05

  Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) offers unparalleled precision for modeling hypertension, cardiovascular remodeling, and vascular smooth muscle cell hypertrophy in both cell and animal systems. This article unpacks advanced workflows, troubleshooting strategies, and novel research frontiers leveraging APExBIO's Angiotensin II for cutting-edge vascular investigations.

• Distinguishing Drug-Induced Growth Arrest and Cell Death In

  2026-08-04

  Schwartz’s dissertation introduces a dual-metric approach for evaluating anti-cancer drug responses in vitro, clarifying the distinct biological effects measured by relative and fractional viability. This work enables more precise interpretation of drug efficacy data and provides a framework for optimizing assay design in cancer research.

• LY2228820: Molecular Insights into p38 MAPK Inhibition for S

  2026-08-04

  Explore how LY2228820, a potent p38 MAP kinase inhibitor, enables systems-level dissection of inflammatory and stress signaling. This article offers a unique multiomics perspective and advanced workflow guidance for translational research.

• Nuanced In Vitro Drug Response Metrics in Cancer Research

  2026-08-03

  Schwartz's dissertation redefines in vitro evaluation of anti-cancer drugs by rigorously distinguishing between growth inhibition and cell death metrics. This approach enables more precise assessment of targeted therapies, such as tyrosine kinase inhibitors, and supports improved experimental and translational oncology research.

• DPPH (2,2-Diphenyl-1-Picrylhydrazyl) Radical in Antioxidant

  2026-08-03

  DPPH (2,2-Diphenyl-1-Picrylhydrazyl) is a validated, stable radical probe for in vitro antioxidant screening. Its colorimetric assay enables rapid quantification of radical scavenging capacity in natural products and drug candidates. Recent studies underscore its benchmark status in comparing the bioactivity of wild versus cultivated botanicals for sustainable antidiabetic research.

• Lypressin Acetate: Applied Protocols for Vasopressor and Ant

  2026-08-02

  Lypressin acetate enables precise modeling of antidiuretic and vasopressor responses, with protocol flexibility that supports both classic and emerging antiviral workflows. Here, we present actionable, evidence-driven guidance for maximizing reproducibility and translational value.

• Mitochondrial Apoptosis and Muscle Atrophy in Ovarian Cancer

  2026-08-01

  This study investigates whether mitochondrial-derived apoptosis and necroptosis drive skeletal muscle atrophy in a robust mouse model of metastatic ovarian cancer. By employing the mitochondrial-targeted antioxidant SkQ1, the authors demonstrate that blocking mitochondrial-linked caspase activation does not prevent muscle fiber atrophy, refining our understanding of cell death pathways in cancer cachexia.

15415 records 1/1028 page Next 12345 下5页 Last page